VGLL1 and breast carcinoma: TCGA RNAseq data analysis indicated that VGLL1 is expressed by several additional cancer types (16 of 34 total), most notably in 75–80% of patients with bladder, ovarian, and basal-type breast cancers, and 15–20% of patients with lung and gastric cancers (Fig. 3b).